RXO, Inc.

RXO, Inc.

28.40
USD
+0.16
(+0.57%)
-0.52EPS
3.37BMarket Cap
Feb 11Next Earn
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
27.29
29.16
40.73
41.58
33.6
34.1
34.08
38.63
Basic EPS, GAAP
0.54
0.37
1.3
0.8
0.03
-2.17
-0.59
-0.52
Free Cash Flow per Basic Share
0.58
-0.19
1.01
2.19
0.21
-0.43
-0.05
-0.43
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
9.28
9.3
5.04
5.08
9.92
9.39
9.19
Tangible Book Value per Share
- -
2.73
2.95
-1.05
-0.89
-0.06
-0.14
-0.1
Basic Weighted Avg Shares
115
115
115
115
117
133
168
169
Sales/Revenue/Turnover
3,141
3,357
4,689
4,796
3,927
4,550
5,742
6,539
Operating Margin (%)
2.93
2.5
4.18
4.59
1.71
0.66
-0.12
0.12
Depreciation Expense
74
76
81
86
67
87
116
108
Net Income, GAAP
62
43
150
92
4
-290
-100
-88
Effective Tax Rate (%)
26.19
24.56
21.47
22.69
- -
- -
- -
- -
Profit Margin (%)
1.97
1.28
3.2
1.92
0.1
-6.37
-1.74
-1.35
Working Capital
- -
233
267
206
114
274
279
352
LT Debt
- -
86
93
565
502
566
578
625
Total Equity
- -
1,068
1,070
587
594
1,612
1,541
1,516
Return on Invested Capital (%)
- -
- -
12.72
7.97
3.35
- -
- -
- -
Return on Capital (%)
- -
- -
12.56
7.89
3.06
- -
- -
- -
Return on Common Equity (%)
- -
- -
14.03
11.1
0.68
-26.29
-6.34
-5.68

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
87
102
102
LT Borrowings
430
459
461
LT Finance Leases
182
167
164
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
165
165
165
Market Capitalization
2,410
4,550
3,375

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,335
1,556
1,607
Cash, Cash Equivalents & STI
21
15
25
Accounts Receivable, Net
1,216
1,444
1,478
Inventories
- -
- -
- -
Total Current Liabilities
1,048
1,227
1,255
Payables & Accruals
951
1,117
1,140
ST Debt
87
102
102
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
24.64%
-4.4%
Free Cash Flow
- -
-202.65%
-85.96%
Net Income, GAAP
- -
-1,460.2%
-65.52%
Sales/Revenue/Turnover
- -
13.18%
26.2%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
913
930
1,040
1,667
4,550
2025
1,433
1,419
1,421
1,469
5,742
2026
1,425
1,774
1,871
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.13
-0.06
-1.81
-0.15
-2.17
2025
-0.18
-0.05
-0.08
-0.27
-0.59
2026
-0.21
-0.05
0.02
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Andrew Wilkerson
Full Time Employees
9,218
Sector
Technology services
Industry
Packaged software
Address
11215 North Community House Road Charlotte NC United States 28277
IPO Date
Oct 27, 2022
Website
rxo.com
Business
RXO delivers asset-light transportation solutions primarily across North America. The company leverages its advanced, proprietary digital freight marketplace to connect shippers with a vast network of carriers, optimizing access to diverse truckload capacity. Beyond brokered freight, they provide integrated services including managed transportation, specialized last-mile delivery, and global freight forwarding. The firm maintains its corporate headquarters in Charlotte, North Carolina.

Company News

  • INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger – OPCH, PTC, RXO and SYNA - IS IT A FAIR DEAL FOR YOU?

  • Are OPCH, PTC, RXO Obtaining Fair Deals for their Shareholders?

  • INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger - OPCH, PTC, RXO and SYNA - IS IT A FAIR DEAL FOR YOU?

  • BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ADT Inc. (NYSE – ADT), RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR)

  • RXO (RXO) Reports Q3 Earnings: What Key Metrics Have to Say

  • RXO (RXO) Q3 Earnings and Revenues Top Estimates

  • RXO Delivers Strong Third-Quarter Results with Profitable Growth and Continued Market Share Gains

  • Despite Fast-paced Momentum, RXO (RXO) Is Still a Bargain Stock

  • Are BRZE, SLN, OPCH, RXO Obtaining Fair Deals for their Shareholders?

  • BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Silence Therapeutics plc (Nasdaq – SLN), Option Care Health, Inc. (Nasdaq – OPCH), RXO Inc. (NYSE – RXO), Sangoma Technologies Corporation (Nasdaq – SANG)

  • Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?

  • Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?

  • C.H. Robinson Bets Its AI Story on RXO—But the Market Isn't Sold

  • Breakfast News: Week in Review

  • $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of RXO, Inc. (NYSE: RXO)

  • C.H. Robinson to Benefit From RXO Acquisition: Here's How

  • RXO Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RXO Inc. - RXO

  • RXO Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RXO Inc. - RXO

  • RXO (RXO) Is Attractively Priced Despite Fast-paced Momentum

  • Top 3 Industrials Stocks You May Want To Dump In October